Cargando…

Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study

BACKGROUND: Multidrug-resistant Pseudomonas aeruginosa infections remain common in hospitals worldwide. We investigated the outcomes associated with the use of ceftolozane-tazobactam for the treatment of these infections. METHODS: Data were collected retrospectively from 20 hospitals across the Unit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallagher, Jason C, Satlin, Michael J, Elabor, Abdulrahman, Saraiya, Nidhi, McCreary, Erin K, Molnar, Esther, El-Beyrouty, Claudine, Jones, Bruce M, Dixit, Deepali, Heil, Emily L, Claeys, Kimberly C, Hiles, Jon, Vyas, Nikunj M, Bland, Christopher M, Suh, Jin, Biason, Kenneth, McCoy, Dorothy, King, Madeline A, Richards, Lynette, Harrington, Nicole, Guo, Yi, Chaudhry, Saira, Lu, Xiaoning, Yu, Daohai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247659/ https://www.ncbi.nlm.nih.gov/pubmed/30488041 http://dx.doi.org/10.1093/ofid/ofy280

Ejemplares similares

Ceftolozane-tazobactam for the Treatment of Multi Drug-resistant Pseudomonas aeruginosa (MDRPA) Infections
por: Molnar, Esther, et al.
Publicado: (2017)

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis
por: McCreary, Erin K, et al.
Publicado: (2020)

2382. Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
por: Elabor, Abdulrahman, et al.
Publicado: (2018)

2435. Clinical Outcomes With Ceftolozane–Tazobactam in Patients With Multidrug-Resistant (MDR) Pseudomonas aeruginosa Bloodstream Infections: A Multi-Center Study
por: King, Madeline, et al.
Publicado: (2018)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR) Pseudomonas aeruginosa
por: Shah, Sunish, et al.
Publicado: (2023)

1109. A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS)
por: Shields, Ryan K, et al.
Publicado: (2023)

1926. Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy
por: Jones, Bruce M, et al.
Publicado: (2018)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis
por: Shah, Sunish, et al.
Publicado: (2021)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess
por: Lewis, Paul O., et al.
Publicado: (2018)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
por: Pezzi, Mario, et al.
Publicado: (2019)

Real-world use of ceftolozane/tazobactam: a systematic literature review
por: Puzniak, Laura, et al.
Publicado: (2021)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
por: Khankhel, Z. S., et al.
Publicado: (2022)

Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections
por: Monogue, Marguerite L, et al.
Publicado: (2023)

2291. Evaluation of Multidrug-Resistant Pseudomonas aeruginosa Isolates in Patients Receiving Ceftolozane/tazobactam
por: Bodo, Emily C, et al.
Publicado: (2019)

2381. Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains With Genetically Defined Resistance
por: Petraitis, Vidmantas, et al.
Publicado: (2018)

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
por: Hong, Mai-Chi, et al.
Publicado: (2013)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
por: Skalweit, Marion J
Publicado: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
por: Jolliff, Jeffrey C., et al.
Publicado: (2016)

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2019)

2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
por: Cabrera, Nicolo, et al.
Publicado: (2019)

1222. Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections
por: Sanders, James, et al.
Publicado: (2021)

1612. Evaluation of the Use of Ceftolozane/Tazobactam for the Treatment of ESBL-producing Enterobacterales Infections Using International Data from SPECTRA (Study of Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam Real World Analysis)
por: Soriano, Alex, et al.
Publicado: (2020)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
por: Li, Junjie, et al.
Publicado: (2020)

In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates
por: Forrester, Jeanne B, et al.
Publicado: (2018)

415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o007jhcif8j3bkccamtli3b656